Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: Enhanced nanofiltration and manufacturing process overview

American Journal of Therapeutics

Volumn 15, Issue 5, 2008, Pages 435-443

  Soluk, Lori ^a   Price, Hugh ^a   Sinclair, Chris ^a   Atalla Mikhail, Dina ^b   Genereux, Maurice ^a  

^a Cangene Corporation   (Canada)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Nanofiltration; Pathogen safety; Planova; Plasma; WinRho

Indexed keywords

HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; RHESUS D ANTIBODY; IMMUNOGLOBULIN;

ANION EXCHANGE CHROMATOGRAPHY; BLOOD SAMPLING; DONOR SELECTION; DRUG FORMULATION; DRUG MANUFACTURE; FRACTIONATION; IMMUNIZATION; NANOFILTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PRION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; ULTRAFILTRATION; VALIDATION PROCESS; VIRAL CONTAMINATION; VIRUS INACTIVATION; VIRUS MORPHOLOGY; VIRUS TRANSMISSION; BLOOD DONOR; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; NANOTECHNOLOGY; VIRUS;

BLOOD DONORS; CHROMATOGRAPHY, ION EXCHANGE; IMMUNOGLOBULINS; NANOTECHNOLOGY; PRIONS; RHO(D) IMMUNE GLOBULIN; SPECIMEN HANDLING; ULTRAFILTRATION; VIRUS INACTIVATION; VIRUSES;

EID: 55249106917     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318160c1b7     Document Type: Review

References (13)

1. Bowman JM, Friesen AD, Pollock JM, et al. WinRho: Rh immune globulin prepared by ion exchange for intravenous use. Can Med Assoc J. 1980;123:1121-1127.
2. WinRho SDF/WinRho SDF Liquid [Rho(D) Immune Globulin Intravenous (human)] prescribing information, Cangene Corporation, Winnipeg, Canada. Westlake Village, CA: Baxter Healthcare Corporation, April 2006.
3. Hong F, Ruiz R, Price H, et al. Safety profile of WinRho anti-D. Semin Hematol. 1998;35(1 Suppl):9-13.
4. Reichl HE, Foster PR, Welch AG, et al. Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang. 2002;83:137-145.
5. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang. 2000;78:86-95.
6. Foster PR. Removal of TSE agents from blood products. Vox Sang. 2004;87(Suppl 2):7-10.
7. Van Holten RW, Autenrieth S, Boose JA, et al. Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter. Transfusion. 2002;42:999-1004.
8. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334:1685-1690.
9. Horowitz B. Investigations into the application of tri(n-butyl)phosphate/ detergent mixtures to blood derivatives. Curr Stud Hematol Blood Transfus. 1989;56:83-96.
10. Data on file. Winnipeg, Manitoba, Canada: Cangene Corporation.
11. Kreil TR, Wieser A, Berting A, et al. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives. Transfusion. 2006;46:1143-1151.
12. Käsermann F, Kempf C. Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol. 2003;84(Pt 11):3173-3176.
13. DNV Consulting. Risk assessment of exposure to vCJD infectivity in blood and blood products. London: United Kingdom Department of Health, 2003.